ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2012
Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Oral Human Abuse Potential of Oxycodone DETERxJournal of clinical pharmacology · 2017Trial
- Purdue's development of abuse-deterrent formulation opioids as a response to market competition: An industry documents analysis.SSM. Qualitative research in health · 2026Article
- Advancement in Opioid Abuse-deterrent Formulation Technologies and Regulatory Expectation.Current drug research reviews · 2025Review
- PLA-PCL microsphere formulation to deter abuse of prescription opioids by smoking.International journal of pharmaceutics · 2022Article
- Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France.Harm reduction journal · 2021Article
- Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States.Frontiers in pharmacology · 2021Article
- Government Legislation in Response to the Opioid Epidemic.Current pain and headache reports · 2019Review
- [Acute pain management in patients with drug dependence syndrome].Schmerz (Berlin, Germany) · 2018Article
- Heroin and Pain.Delaware journal of public health · 2017Article
- Acute pain management in patients with drug dependence syndrome.Pain reports · 2017Article
- The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.Advances in therapy · 2015Article
- Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.Therapeutic advances in drug safety · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased use of opioid pain medication has been mirrored by the increased misuse and abuse of these drugs. As part of a multidisciplinary approach to this epidemic, pharmaceutical companies, with the encouragement of the Food and Drug Administration, have increased the development of abuse-deterrent formulations. While all have the goal of treating pain while mitigating misuse and abuse, there are different technologies utilized to impart the abuse-deterrent properties. The goal of this paper is to review the basis of abuse-deterrent formulations, the different types and approaches of some of the abuse-deterrent products, and their current regulatory status in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.